| |
| |
|
| Insider
Information: |
Fuchs Henry J |
| Relationship: |
|
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
222,228 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$18,063,061 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
222,228 |
|
|
| Total
Value |
$18,063,061 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP & Chief Medical Of... |
2008-11-18 |
14,891 |
2006-05-15 |
0 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director |
2012-06-19 |
0 |
2007-12-05 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
President, Worldwide R&D |
2024-03-15 |
196,872 |
2009-03-02 |
0 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director |
2019-11-08 |
0 |
2014-04-01 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2023-01-20 |
10,465 |
2020-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
294 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 11 of 12
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
955 |
7,436 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-07-01 |
4 |
A |
$58.86 |
$12,478 |
D/D |
212 |
7,648 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-10-01 |
4 |
A |
$67.28 |
$12,447 |
D/D |
185 |
7,833 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2019-11-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,833) |
0 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2020-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,136 |
137,981 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-13 |
4 |
D |
$84.50 |
$886,912 |
D/D |
(10,496) |
127,485 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,220 |
145,705 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-03-20 |
4 |
D |
$73.05 |
$426,320 |
D/D |
(5,836) |
139,869 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-04-20 |
4 |
AS |
$90.00 |
$1,549,170 |
D/D |
(17,213) |
122,656 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-04-24 |
4 |
AS |
$95.34 |
$1,917,617 |
D/D |
(20,000) |
102,656 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-04-30 |
4 |
A |
$62.59 |
$21,217 |
D/D |
339 |
102,995 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-07-13 |
4 |
OE |
$63.10 |
$1,518,094 |
D/D |
23,011 |
126,006 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-07-13 |
4 |
AS |
$130.00 |
$2,991,430 |
D/D |
(23,011) |
102,995 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-07-20 |
4 |
AS |
$130.00 |
$16,430,570 |
D/D |
(126,389) |
102,995 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2020-07-20 |
4 |
OE |
$63.10 |
$8,337,656 |
D/D |
126,389 |
229,384 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2020-08-10 |
4 |
OE |
$20.54 |
$205,400 |
D/D |
10,000 |
12,000 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2020-08-10 |
4 |
AS |
$127.52 |
$1,313,783 |
D/D |
(10,000) |
2,000 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2020-12-15 |
4 |
AS |
$230.19 |
$2,333,907 |
D/D |
(10,000) |
2,000 |
0 |
% |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2020-12-15 |
4 |
OE |
$20.54 |
$205,400 |
D/D |
10,000 |
12,000 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2021-01-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,475 |
3,475 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,320 |
118,315 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-15 |
4 |
D |
$78.39 |
$584,789 |
D/D |
(7,460) |
110,855 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-16 |
4 |
D |
$77.21 |
$174,417 |
D/D |
(2,259) |
108,596 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
President, Worldwide R&D |
• – – |
2021-03-22 |
4 |
D |
$78.52 |
$192,688 |
D/D |
(2,454) |
106,142 |
0 |
- |
|
294 Records found
|
|
Page 11 of 12 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
